Exchange: NASDAQ·Updated 07:30 PM EST

MGNX News

News
all
press releases
MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -240.00% and -69.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -240.00% and -69.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
ResMed (RMD) delivered earnings and revenue surprises of +8.99% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Zacks
Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
Zacks
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
Zacks
MacroGenics (MGNX) delivered earnings and revenue surprises of +32.50% and -25.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sanara MedTech (SMTI) delivered earnings and revenue surprises of +150.00% and -4.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.
Zacks

Advertisement|Remove ads.